[go: up one dir, main page]

DK3439653T3 - Reduktion af tumorbyrde ved administration af ccr1- antagonister i kombination med pd-1-hæmmere eller pd-l1-hæmmere - Google Patents

Reduktion af tumorbyrde ved administration af ccr1- antagonister i kombination med pd-1-hæmmere eller pd-l1-hæmmere Download PDF

Info

Publication number
DK3439653T3
DK3439653T3 DK17779801.4T DK17779801T DK3439653T3 DK 3439653 T3 DK3439653 T3 DK 3439653T3 DK 17779801 T DK17779801 T DK 17779801T DK 3439653 T3 DK3439653 T3 DK 3439653T3
Authority
DK
Denmark
Prior art keywords
inhibitors
administrating
combination
tumor burden
reducing tumor
Prior art date
Application number
DK17779801.4T
Other languages
English (en)
Inventor
Israel Charo
Heiyoun Jung
Penglie Zhang
Thomas J Schall
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Application granted granted Critical
Publication of DK3439653T3 publication Critical patent/DK3439653T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK17779801.4T 2016-04-07 2017-04-06 Reduktion af tumorbyrde ved administration af ccr1- antagonister i kombination med pd-1-hæmmere eller pd-l1-hæmmere DK3439653T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662319689P 2016-04-07 2016-04-07
PCT/US2017/026290 WO2017176965A1 (en) 2016-04-07 2017-04-06 Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Publications (1)

Publication Number Publication Date
DK3439653T3 true DK3439653T3 (da) 2021-03-29

Family

ID=59999231

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17779801.4T DK3439653T3 (da) 2016-04-07 2017-04-06 Reduktion af tumorbyrde ved administration af ccr1- antagonister i kombination med pd-1-hæmmere eller pd-l1-hæmmere

Country Status (20)

Country Link
US (2) US10568870B2 (da)
EP (1) EP3439653B1 (da)
JP (2) JP7539231B2 (da)
KR (1) KR102370704B1 (da)
CN (1) CN109310677A (da)
AR (1) AR108202A1 (da)
AU (1) AU2017246460B2 (da)
BR (1) BR112018070361A2 (da)
CA (1) CA3019391A1 (da)
DK (1) DK3439653T3 (da)
ES (1) ES2864148T3 (da)
IL (1) IL261998B2 (da)
MX (1) MX384929B (da)
PL (1) PL3439653T3 (da)
PT (1) PT3439653T (da)
RU (1) RU2745195C2 (da)
SG (1) SG11201808626WA (da)
TW (1) TWI808938B (da)
WO (1) WO2017176965A1 (da)
ZA (1) ZA201806633B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089495A1 (en) 2012-12-07 2014-06-12 Chemocentryx, Inc. Diazole lactams
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
PL3439653T3 (pl) 2016-04-07 2021-07-05 Chemocentryx, Inc. Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1
EP3474845B1 (en) 2016-06-27 2024-03-20 ChemoCentryx, Inc. Immunomodulator compounds
EP3431105B1 (en) * 2017-03-29 2020-01-01 Shionogi&Co., Ltd. Medicinal composition for treating cancer
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
IL272258B (en) 2017-07-28 2022-08-01 Chemocentryx Inc Immunomodulator compounds
EP3664793B1 (en) 2017-08-08 2022-06-29 ChemoCentryx, Inc. Macrocyclic immunomodulators
RU2020124143A (ru) * 2017-12-22 2022-01-24 Кодадженикс Инк. Рекомбинантный вирус с областью деоптимизированной пары кодонов и его применение для лечения рака
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
BR112020018188A2 (pt) 2018-03-08 2021-02-02 Codagenix Inc. flavivírus atenuados
AU2019285641A1 (en) 2018-06-15 2021-04-08 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
JP7329860B2 (ja) * 2018-06-15 2023-08-21 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ｓ－エクオールを用いた乳癌の治療及び予防方法
JP2021536445A (ja) * 2018-08-29 2021-12-27 ケモセントリックス，インコーポレイティド 小型分子ｐｄ−ｌ１インヒビターによる癌治療法
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
CN113544144A (zh) 2018-09-19 2021-10-22 高山免疫科学股份有限公司 变体cd80融合蛋白和相关构建体的方法和用途
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
PT3880186T (pt) 2018-11-14 2024-05-28 Regeneron Pharma Administração intralesional de inibidores de pd-1 para o tratamento do cancro de pele
SG11202108089SA (en) 2019-02-28 2021-08-30 Regeneron Pharma Administration of pd-1 inhibitors for treating skin cancer
CA3129963A1 (en) 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
CA3145303A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
CA3148291A1 (en) * 2019-09-11 2021-03-18 Boehringer Ingelheim Io Canada, Inc. Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies
GB201918692D0 (en) * 2019-12-18 2020-01-29 Cambridge Entpr Ltd Treatment and prognosis of pancreatic cancer
US20230331858A1 (en) * 2019-12-24 2023-10-19 Neoleukin Therapeutics, Inc. Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
CN115666724A (zh) 2020-05-26 2023-01-31 瑞泽恩制药公司 通过施用pd-1抑制剂抗体西米普利单抗来治疗宫颈癌的方法
JP2023540217A (ja) 2020-08-26 2023-09-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することによりがんを処置する方法
CA3170207A1 (en) 2020-09-03 2022-03-10 Chieh-I CHEN Methods of treating cancer pain by administering a pd-1 inhibitor
EP4228627A4 (en) * 2020-10-13 2024-11-06 Board of Regents, The University of Texas System COMBINATORIAL IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PANCREATIC DUCT ADENOCARCINOMA
WO2022204672A1 (en) 2021-03-23 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
AU2022314735A1 (en) 2021-07-19 2024-02-22 Regeneron Pharmaceuticals, Inc. Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
US20250152643A1 (en) 2022-02-17 2025-05-15 Regeneron Pharmaceuticals, Inc. Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
WO2023230220A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
WO2025080538A1 (en) 2023-10-09 2025-04-17 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
DE19539091A1 (de) 1995-10-20 1997-04-24 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
US6756385B2 (en) 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
KR20030030029A (ko) 2000-09-22 2003-04-16 니혼노야쿠가부시키가이샤 Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
BRPI0409949A (pt) 2003-05-01 2006-04-25 Bristol Myers Squibb Co compostos de pirazol amida aril-substituìda úteis como inibidores de cinase
EP1883646A1 (en) 2005-05-19 2008-02-06 Cv Therapeutics, Inc. A1 adenosine receptor agonists
ES2543714T3 (es) 2005-06-22 2015-08-21 Chemocentryx, Inc. Compuestos de azaindazol y métodos de uso
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
FR2887450B1 (fr) 2005-06-23 2007-08-24 Rhodia Chimie Sa Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
WO2007026834A1 (ja) 2005-09-01 2007-03-08 Kumiai Chemical Industry Co., Ltd. ピラゾール誘導体及び農園芸用除草剤
WO2007044804A2 (en) 2005-10-11 2007-04-19 Chemocentryx, Inc. Piperidine derivatives and methods of use
US20090252779A1 (en) 2006-06-22 2009-10-08 Chemocentryx, Inc. Azaindazole compounds and methods of use
CA2675511A1 (en) 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
WO2008072724A1 (ja) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. ピラゾール誘導体
US7786157B2 (en) 2007-03-16 2010-08-31 Chemocentryx, Inc. OXO-imidazolidines as modulators of chemokine receptors
CN101743238B (zh) 2007-05-22 2014-04-30 凯莫森特里克斯股份有限公司 3-(咪唑基)-吡唑并[3,4-b]吡啶
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2170309B1 (en) 2007-06-22 2016-10-26 Hydra Biosciences, Inc. 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
AU2008321823B2 (en) 2007-11-13 2013-03-07 Taisho Pharmaceutical Co., Ltd. Phenylpyrazole derivatives
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2297112B1 (en) 2008-05-06 2013-04-03 Boehringer Ingelheim International GmbH Pyrazole compounds as ccr1 antagonists
US20120108614A1 (en) 2008-05-14 2012-05-03 Chong Jayhong A Compounds and compositions for treating chemical warfare agent-induced injuries
PL2323663T3 (pl) * 2008-09-11 2015-08-31 Chemocentryx Inc 4-amino-3-(imidazolilo)-pirazolo[3,4,-d]pirymidyny
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
GB0915892D0 (en) 2009-09-10 2009-10-14 Smithkline Beecham Corp Compounds
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN103732238A (zh) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 用于免疫调节的治疗性化合物
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
CN104159911A (zh) 2012-03-07 2014-11-19 奥瑞基尼探索技术有限公司 作为免疫调节剂的模拟肽化合物
US9422339B2 (en) 2012-03-29 2016-08-23 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014035967A2 (en) * 2012-08-27 2014-03-06 Chemocentryx, Inc. Antagonists of chemokine receptors
WO2014089495A1 (en) 2012-12-07 2014-06-12 Chemocentryx, Inc. Diazole lactams
EP2935227B1 (en) 2012-12-21 2017-09-13 ChemoCentryx, Inc. Diazole amides as ccr1 receptor antagonists
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
DK3021869T3 (da) * 2013-07-16 2020-09-21 Hoffmann La Roche Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere
KR102232153B1 (ko) 2013-08-20 2021-03-24 머크 샤프 앤드 돔 코포레이션 Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료
EA029901B1 (ru) 2013-09-04 2018-05-31 Бристол-Майерс Сквибб Компани Соединения для применения в качестве иммуномодуляторов
DK3363790T3 (da) 2013-09-06 2020-04-27 Aurigene Discovery Tech Ltd 1,2,4-oxadiazolderivater som immunmodulatorer
KR20160075506A (ko) 2013-09-06 2016-06-29 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서 사이클릭 펩티도미메틱 화합물
CU24345B1 (es) 2013-09-06 2018-05-08 Aurigene Discovery Tech Ltd Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
AU2015267052A1 (en) * 2014-05-27 2016-12-15 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AR101210A1 (es) * 2014-07-15 2016-11-30 Genentech Inc Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
MA40132B1 (fr) 2014-09-11 2019-04-30 Bristol Myers Squibb Co Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
CU24509B1 (es) 2015-03-10 2021-05-12 Aurigene Discovery Tech Ltd Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
BR112017019306A2 (pt) 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos de 1,3,4-oxadiazol e tiadiazol como imunomoduladores
CU20170116A7 (es) 2015-03-10 2018-06-05 Aurigene Discovery Tech Ltd Compuestos cíclicos terapéuticos como inmunomoduladores
KR20170125931A (ko) 2015-03-10 2017-11-15 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서의 3-치환된 1,3,4-옥사다이아졸 및 티아다이아졸 화합물
SG11201706902SA (en) 2015-03-10 2017-09-28 Aurigene Discovery Tech Ltd 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10110466B2 (en) * 2015-11-23 2018-10-23 Tyco Electronics Subsea Communications Llc Optical communication system with distributed wet plant manager
PL3439653T3 (pl) 2016-04-07 2021-07-05 Chemocentryx, Inc. Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1

Also Published As

Publication number Publication date
WO2017176965A1 (en) 2017-10-12
BR112018070361A2 (pt) 2019-01-29
NZ746960A (en) 2025-05-30
TW201801724A (zh) 2018-01-16
IL261998B (en) 2022-11-01
KR102370704B1 (ko) 2022-03-03
JP2022130424A (ja) 2022-09-06
ZA201806633B (en) 2021-04-28
RU2018138828A (ru) 2020-05-15
RU2018138828A3 (da) 2020-08-12
RU2745195C2 (ru) 2021-03-22
TWI808938B (zh) 2023-07-21
US20170290808A1 (en) 2017-10-12
PT3439653T (pt) 2021-03-25
EP3439653B1 (en) 2021-01-20
CA3019391A1 (en) 2017-10-12
EP3439653A1 (en) 2019-02-13
KR20190020291A (ko) 2019-02-28
MX384929B (es) 2025-03-14
US11744822B2 (en) 2023-09-05
US10568870B2 (en) 2020-02-25
IL261998B2 (en) 2023-03-01
AR108202A1 (es) 2018-07-25
AU2017246460B2 (en) 2021-04-22
EP3439653A4 (en) 2019-12-04
AU2017246460A1 (en) 2018-10-25
IL261998A (en) 2018-10-31
PL3439653T3 (pl) 2021-07-05
US20200289472A1 (en) 2020-09-17
JP2019510832A (ja) 2019-04-18
ES2864148T3 (es) 2021-10-13
SG11201808626WA (en) 2018-10-30
MX2018012132A (es) 2019-03-28
CN109310677A (zh) 2019-02-05
JP7611189B2 (ja) 2025-01-09
JP7539231B2 (ja) 2024-08-23

Similar Documents

Publication Publication Date Title
DK3439653T3 (da) Reduktion af tumorbyrde ved administration af ccr1- antagonister i kombination med pd-1-hæmmere eller pd-l1-hæmmere
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
IL258688A (en) Compositions and methods for viral cancer neoepitopes
DK3458074T3 (da) COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
IL249061B (en) Combination, composition, and method of administering the combination or composition to animals
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
LT3292153T (lt) Cd30xcd16a antikūno derinys su antagonistiniu antikūnu prieš pd-1 skirtas terapijai
SI3262037T1 (sl) Novi derivati kinolina za uporabo v zdravljenju in preprečevanju virusnih okužb
SI3069720T1 (sl) Farmacevtski sestavek, ki vsebuje derivate glutarimida, in njegova uporaba za zdravljenje eozinofilnih bolezni
ME03066B (me) Derivati izoindolina za upotrebu u lečenju virusne infekcije
IL251443A0 (en) Compositions and methods for cannabinoid coatings for use in drug delivery
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
DK3185867T3 (da) Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni
DK3151831T3 (da) Priming af kræftceller med lav dosis af naltrexon
HRP20181332T1 (hr) Derivati benzimidazola i njihovi farmaceutski pripravci, namijenjeni liječenju upalnih poremećaja
DK3275452T3 (da) Farmaceutisk sammensætning med silibinin
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK2984184T3 (da) Anvendelse af dnq eller dnq-87 i kombination med en parp1-inhibitor til behandlingen af cancer
HRP20181582T1 (hr) Formulacija atazanavira i kobicistata za liječenje hiv-a
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
DK3283064T3 (da) Derivater til anvendelse i behandling af muskelatrofi
LT3229790T (lt) Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme